Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Assets (2019 - 2025)

Fennec Pharmaceuticals filings provide 7 years of Non-Current Assets readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 326.76% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 326.76% increase, with the full-year FY2025 number at $3.5 million, up 326.76% from a year prior.
  • Non-Current Assets hit $3.5 million in Q4 2025 for Fennec Pharmaceuticals, up from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.1 million in Q2 2025 to a low of $6000.0 in Q4 2023.
  • Median Non-Current Assets over the past 5 years was $211000.0 (2022), compared with a mean of $998421.1.
  • Biggest five-year swings in Non-Current Assets: plummeted 97.16% in 2023 and later surged 13600.0% in 2024.
  • Fennec Pharmaceuticals' Non-Current Assets stood at $27000.0 in 2021, then skyrocketed by 681.48% to $211000.0 in 2022, then plummeted by 97.16% to $6000.0 in 2023, then surged by 13600.0% to $822000.0 in 2024, then skyrocketed by 326.76% to $3.5 million in 2025.
  • The last three reported values for Non-Current Assets were $3.5 million (Q4 2025), $3.2 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.